Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results
We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-08, Vol.15 (8), p.e0237330-e0237330 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0237330 |
|---|---|
| container_issue | 8 |
| container_start_page | e0237330 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Matsubara, Mio Sakurada, Yoichi Sugiyama, Atsushi Fukuda, Yoshiko Parikh, Ravi Kashiwagi, Kenji Falcão, Manuel Alberto de Almeida e Sousa |
| description | We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6±1.1 months) (P = 0.0055, Group 0: 19.1±6.9, Group 2: 12.8±7.9, Group 3: 11.5±9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years. |
| doi_str_mv | 10.1371/journal.pone.0237330 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2432837112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A632200676</galeid><doaj_id>oai_doaj_org_article_c709306a25b04bc1b89a46d26fdd2890</doaj_id><sourcerecordid>A632200676</sourcerecordid><originalsourceid>FETCH-LOGICAL-c669t-bf7fb0da57bb7ee6e49eb0e19b40be06a48c2bb77363a82f73b4703d677b22f93</originalsourceid><addsrcrecordid>eNqNk9uKFDEQhhtR3HX1DQQDgujFjOmkJ-n2QlgWDwMLC-vhNuRQPZ0h02mT9Kz9Mj6rmZ1RdmQvpC86VH35K_VTVRTPSzwvKS_frv0Yeunmg-9hjgnllOIHxWnZUDJjBNOHd84nxZMY1xgvaM3Y4-KEEl5jviCnxa9riFkhAkoeDZ1P3ky93FiNUgdBDhPSfqNsDwbd2NQh26cgtzYFkA7J1lkFQcOQUOsDGrybBm9NTunOh_1pK6MenR9k6iZkYIDe2H6FfI9acM7fzGCCXCRHk_X9OzKbQAYUII4uxafFo1a6CM8O_7Pi28cPXy8-zy6vPi0vzi9nmrEmzVTLW4WNXHClOACDqgGFoWxUhRVgJqtak5zilFFZk5ZTVXFMDeNcEdI29Kx4sdcdnI_iYG0UpKKkzmaXJBPLPWG8XIsh2I0Mk_DSituADyshQ7LagdAcNzQXJQuFK6VLVTeyYoaw1hhSNzhrvT9UG9UGjIadqe5I9DjT206s_FbwqqwbtsgCrw8Cwf8YISaxsVFnO2UPfrx9NyUVxuWus5f_oPd3d6BWMjdg-9bnunonKs4ZJQRjxlmm5vdQ-TOQJybPYWtz_OjCm6MLmUnwM63kGKNYfrn-f_bq-zH76g7b5VlMXfRu3E1QPAarPaiDjzFA-9fkEovdGv1xQ-zWSBzWiP4GaEQSZA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2432837112</pqid></control><display><type>article</type><title>Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Matsubara, Mio ; Sakurada, Yoichi ; Sugiyama, Atsushi ; Fukuda, Yoshiko ; Parikh, Ravi ; Kashiwagi, Kenji ; Falcão, Manuel Alberto de Almeida e Sousa</creator><contributor>Falcão, Manuel Alberto de Almeida e Sousa</contributor><creatorcontrib>Matsubara, Mio ; Sakurada, Yoichi ; Sugiyama, Atsushi ; Fukuda, Yoshiko ; Parikh, Ravi ; Kashiwagi, Kenji ; Falcão, Manuel Alberto de Almeida e Sousa ; Falcão, Manuel Alberto de Almeida e Sousa</creatorcontrib><description>We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6±1.1 months) (P = 0.0055, Group 0: 19.1±6.9, Group 2: 12.8±7.9, Group 3: 11.5±9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0237330</identifier><identifier>PMID: 32780752</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Acuity ; Aflibercept ; Biology and Life Sciences ; Care and treatment ; Combined modality therapy ; Dosage and administration ; Eye ; Eye (anatomy) ; Injection ; Macular degeneration ; Medical imaging ; Medicine ; Medicine and Health Sciences ; Methods ; Patient outcomes ; Photochemotherapy ; Photodynamic therapy ; Photography ; Research and Analysis Methods ; Retina ; Scars ; Social Sciences ; Statistical analysis ; Studies ; Vascular diseases ; Vascular endothelial growth factor ; Visual acuity</subject><ispartof>PloS one, 2020-08, Vol.15 (8), p.e0237330-e0237330</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Matsubara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Matsubara et al 2020 Matsubara et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c669t-bf7fb0da57bb7ee6e49eb0e19b40be06a48c2bb77363a82f73b4703d677b22f93</citedby><cites>FETCH-LOGICAL-c669t-bf7fb0da57bb7ee6e49eb0e19b40be06a48c2bb77363a82f73b4703d677b22f93</cites><orcidid>0000-0001-8506-8503 ; 0000-0002-2894-0454</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418965/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418965/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2100,2926,23865,27923,27924,53790,53792,79371,79372</link.rule.ids></links><search><contributor>Falcão, Manuel Alberto de Almeida e Sousa</contributor><creatorcontrib>Matsubara, Mio</creatorcontrib><creatorcontrib>Sakurada, Yoichi</creatorcontrib><creatorcontrib>Sugiyama, Atsushi</creatorcontrib><creatorcontrib>Fukuda, Yoshiko</creatorcontrib><creatorcontrib>Parikh, Ravi</creatorcontrib><creatorcontrib>Kashiwagi, Kenji</creatorcontrib><creatorcontrib>Falcão, Manuel Alberto de Almeida e Sousa</creatorcontrib><title>Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results</title><title>PloS one</title><description>We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6±1.1 months) (P = 0.0055, Group 0: 19.1±6.9, Group 2: 12.8±7.9, Group 3: 11.5±9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years.</description><subject>Acuity</subject><subject>Aflibercept</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Combined modality therapy</subject><subject>Dosage and administration</subject><subject>Eye</subject><subject>Eye (anatomy)</subject><subject>Injection</subject><subject>Macular degeneration</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Patient outcomes</subject><subject>Photochemotherapy</subject><subject>Photodynamic therapy</subject><subject>Photography</subject><subject>Research and Analysis Methods</subject><subject>Retina</subject><subject>Scars</subject><subject>Social Sciences</subject><subject>Statistical analysis</subject><subject>Studies</subject><subject>Vascular diseases</subject><subject>Vascular endothelial growth factor</subject><subject>Visual acuity</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9uKFDEQhhtR3HX1DQQDgujFjOmkJ-n2QlgWDwMLC-vhNuRQPZ0h02mT9Kz9Mj6rmZ1RdmQvpC86VH35K_VTVRTPSzwvKS_frv0Yeunmg-9hjgnllOIHxWnZUDJjBNOHd84nxZMY1xgvaM3Y4-KEEl5jviCnxa9riFkhAkoeDZ1P3ky93FiNUgdBDhPSfqNsDwbd2NQh26cgtzYFkA7J1lkFQcOQUOsDGrybBm9NTunOh_1pK6MenR9k6iZkYIDe2H6FfI9acM7fzGCCXCRHk_X9OzKbQAYUII4uxafFo1a6CM8O_7Pi28cPXy8-zy6vPi0vzi9nmrEmzVTLW4WNXHClOACDqgGFoWxUhRVgJqtak5zilFFZk5ZTVXFMDeNcEdI29Kx4sdcdnI_iYG0UpKKkzmaXJBPLPWG8XIsh2I0Mk_DSituADyshQ7LagdAcNzQXJQuFK6VLVTeyYoaw1hhSNzhrvT9UG9UGjIadqe5I9DjT206s_FbwqqwbtsgCrw8Cwf8YISaxsVFnO2UPfrx9NyUVxuWus5f_oPd3d6BWMjdg-9bnunonKs4ZJQRjxlmm5vdQ-TOQJybPYWtz_OjCm6MLmUnwM63kGKNYfrn-f_bq-zH76g7b5VlMXfRu3E1QPAarPaiDjzFA-9fkEovdGv1xQ-zWSBzWiP4GaEQSZA</recordid><startdate>20200811</startdate><enddate>20200811</enddate><creator>Matsubara, Mio</creator><creator>Sakurada, Yoichi</creator><creator>Sugiyama, Atsushi</creator><creator>Fukuda, Yoshiko</creator><creator>Parikh, Ravi</creator><creator>Kashiwagi, Kenji</creator><creator>Falcão, Manuel Alberto de Almeida e Sousa</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8506-8503</orcidid><orcidid>https://orcid.org/0000-0002-2894-0454</orcidid></search><sort><creationdate>20200811</creationdate><title>Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results</title><author>Matsubara, Mio ; Sakurada, Yoichi ; Sugiyama, Atsushi ; Fukuda, Yoshiko ; Parikh, Ravi ; Kashiwagi, Kenji ; Falcão, Manuel Alberto de Almeida e Sousa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c669t-bf7fb0da57bb7ee6e49eb0e19b40be06a48c2bb77363a82f73b4703d677b22f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acuity</topic><topic>Aflibercept</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Combined modality therapy</topic><topic>Dosage and administration</topic><topic>Eye</topic><topic>Eye (anatomy)</topic><topic>Injection</topic><topic>Macular degeneration</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Patient outcomes</topic><topic>Photochemotherapy</topic><topic>Photodynamic therapy</topic><topic>Photography</topic><topic>Research and Analysis Methods</topic><topic>Retina</topic><topic>Scars</topic><topic>Social Sciences</topic><topic>Statistical analysis</topic><topic>Studies</topic><topic>Vascular diseases</topic><topic>Vascular endothelial growth factor</topic><topic>Visual acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsubara, Mio</creatorcontrib><creatorcontrib>Sakurada, Yoichi</creatorcontrib><creatorcontrib>Sugiyama, Atsushi</creatorcontrib><creatorcontrib>Fukuda, Yoshiko</creatorcontrib><creatorcontrib>Parikh, Ravi</creatorcontrib><creatorcontrib>Kashiwagi, Kenji</creatorcontrib><creatorcontrib>Falcão, Manuel Alberto de Almeida e Sousa</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsubara, Mio</au><au>Sakurada, Yoichi</au><au>Sugiyama, Atsushi</au><au>Fukuda, Yoshiko</au><au>Parikh, Ravi</au><au>Kashiwagi, Kenji</au><au>Falcão, Manuel Alberto de Almeida e Sousa</au><au>Falcão, Manuel Alberto de Almeida e Sousa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results</atitle><jtitle>PloS one</jtitle><date>2020-08-11</date><risdate>2020</risdate><volume>15</volume><issue>8</issue><spage>e0237330</spage><epage>e0237330</epage><pages>e0237330-e0237330</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6±1.1 months) (P = 0.0055, Group 0: 19.1±6.9, Group 2: 12.8±7.9, Group 3: 11.5±9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>32780752</pmid><doi>10.1371/journal.pone.0237330</doi><tpages>e0237330</tpages><orcidid>https://orcid.org/0000-0001-8506-8503</orcidid><orcidid>https://orcid.org/0000-0002-2894-0454</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-08, Vol.15 (8), p.e0237330-e0237330 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2432837112 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Acuity Aflibercept Biology and Life Sciences Care and treatment Combined modality therapy Dosage and administration Eye Eye (anatomy) Injection Macular degeneration Medical imaging Medicine Medicine and Health Sciences Methods Patient outcomes Photochemotherapy Photodynamic therapy Photography Research and Analysis Methods Retina Scars Social Sciences Statistical analysis Studies Vascular diseases Vascular endothelial growth factor Visual acuity |
| title | Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A24%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20photodynamic%20therapy%20combined%20with%20intravitreal%20aflibercept%20for%20polypoidal%20choroidal%20vasculopathy%20depending%20on%20fellow-eye%20condition:2-year%20results&rft.jtitle=PloS%20one&rft.au=Matsubara,%20Mio&rft.date=2020-08-11&rft.volume=15&rft.issue=8&rft.spage=e0237330&rft.epage=e0237330&rft.pages=e0237330-e0237330&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0237330&rft_dat=%3Cgale_plos_%3EA632200676%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2432837112&rft_id=info:pmid/32780752&rft_galeid=A632200676&rft_doaj_id=oai_doaj_org_article_c709306a25b04bc1b89a46d26fdd2890&rfr_iscdi=true |